NASDAQ:PALI

Palisade Bio Q2 2026 Earnings Results & Report

Palisade Bio logo
$0.84 -0.09 (-9.24%)
Closing price 04:00 PM Eastern
Extended Trading
$0.86 +0.02 (+2.39%)
As of 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Palisade Bio beat analyst earnings expectations and met on revenue in its Q2 2026 results, released August 10, 2026. The company reported EPS of -$0.05 versus the -$0.0522 consensus estimate, while revenue of $500 thousand matched the $500 thousand estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Palisade Bio EPS Results

Actual EPS
-$0.05
Consensus EPS
-$0.0522
Beat/Miss
Beat by +$0.0022
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Palisade Bio Revenue Results

Actual Revenue
$500 thousand
Expected Revenue
$500 thousand
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

Palisade Bio Q2 2026 Earnings FAQ

Palisade Bio (NASDAQ:PALI) reported earnings of -$0.05 per share for Q2 2026, beating the consensus estimate of -$0.0522. The report was announced on Monday, August 10, 2026.

Palisade Bio reported revenue of $500 thousand for Q2 2026, against a consensus estimate of $500 thousand.

Palisade Bio Earnings Headlines

FY2026 EPS Estimate for Palisade Bio Reduced by Analyst
FY2026 EPS Forecast for Palisade Bio Reduced by Analyst
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
See More Palisade Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Palisade Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Palisade Bio and other key companies, straight to your email.

About Palisade Bio

Palisade Bio (NASDAQ:PALI) is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, with a focus on oral treatments for inflammatory bowel conditions.

Its pipeline includes PALI-2108, an investigational, gut-targeted PDE4 inhibitor being developed for ulcerative colitis and fibrostenotic Crohn’s disease. The company has also developed LB1148, an investigational serine protease inhibitor studied for its potential to support bowel function and reduce complications after abdominal surgery.

Palisade Bio’s candidates are in clinical development and are not approved for commercial use.

View Palisade Bio Profile